The reversal effect of magnetic Fe3O4 nanoparticles loaded with cisplatin on SKOV3/DDP ovarian carcinoma cells

International Journal of Nanomedicine

Volumn 4, Issue 1, 2009, Pages 107-114

  Jiang, Zhi ^a   Chen, Bao An ^a   Xia, Guo Hua ^a   Wu, Qiang ^b   Zhang, Yu ^a   Hong, Tie Yan ^a   Zhang, Wei ^a   Cheng, Jian ^a   Gao, Feng ^a   Liu, Li Jie ^c   Li, Xiao Mao ^d   Wang, Xue Mei ^c  

^a AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

^b JIANGSU CANCER HOSPITAL   (China)

^c SOUTHEAST UNIVERSITY   (China)

^d SAARLAND UNIVERSITY   (Germany)

Author keywords

Bcl 2; LRP; Magnetic nanoparticles of Fe3O4; MDR1; Multidrug resistance reversal; P gp; SKOV3 DDP

Indexed keywords

CISPLATIN; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BCL 2; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

APOPTOSIS; ARTICLE; ATOMIC EMISSION SPECTROMETRY; CANCER CELL CULTURE; CELL ASSAY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INCUBATION TIME; MULTIDRUG RESISTANCE; OVARY CARCINOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; FEMALE; FERRIC COMPOUNDS; HUMANS; MAGNETICS; NANOPARTICLES; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

EID: 66149102454     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Kurzeder C, Sauer G, Deissler H. Molecular targets of ovarian carcinomas with acquired resistance to platinum/taxane chemotherapy. Curr Cancer Drug Targets. 2006;6:207-227.
2. Meyn RE, Stephens LC, Hunter MR, et al. Kinetics of cisplatin-induced apoptosis in murine mammary and ovarian adenocarcinomas. Int J Cancer. 1995;60:725-729.
3. Sikic BI, Fisher GA, Lum BL, et al. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol. 1997;40:S13-S19.
4. Yoshinao O, Yoshihiro O, Yuji B, et al. Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: Their correlation with activated Akt, LRP/MVP and P-glycoprotein expression. Cancer Sci. 2007;98: 1020-1026.
5. Horvath V, Blanarova O, Svihalkova-Sindlerova L, et al. Platinum (IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells. Gynecol Oncol. 2006;102:32-40.
6. Sato S, Kigawa J, Minagawa Y, et al. Chemosensistive and p53-dependent apoptosis in epithelial ovarian carcinoma. Cancer. 1999;86: 1307-1313.
7. Sasaki H, Sheng Y, Kotsuji F, et al. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res. 2000;60:5659-5666.
8. Fraser M, Leung BM, Yan X, et al. P53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemo-resistance in human ovarian cancer cells. Cancer Res. 2003;63:7081-7088.
9. Dan HC, Sun M, Kaneko S, et al. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem. 2004;279:5405-5412.
10. Villedieu M, Louis MH, Dutoit S, et al. Absence of Bcl-X-L down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells, Gynecol Oncol. 2007;105:31-34.
11. 4. Au and daunomycin on K562/A02. Southeast Univ (Med Sci Edu). 2007;26:157-60.
12. 4 loaded with adriamycin and tetrandrine in K562/AO2 leukemic cells. Int J Nanomedicine. 2008;3:277-286.
13. Feng SS, Mu L, Win KY, et al. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem. 2004;11:412-424.
14. 4 nanoparticles and their biomedical applications. Biomaterials. 2005;26:729-738.
15. Gao H, Wang J, Shen X, et al. Preparation of magnetic polybutylcyanoacrylate nanosheres encapsulated with aclacinomycin A and its effect on gastric tumor, World J Gastroenterol. 2004;10:2010-2013.
16. Li BH, Hu DX, Zhao LY. Investigate the molecular mechanism of the cisplatin-resistant with human epithelial ovarian cancer cell line SKOV3 and SKOV3/DDP cultured in vitro. Zhong Hua Fu You Baojian. 2005;20:1195-1197.
17. Dalton WS. Mechanisms of drug resistance in hematologic malignancies. Semin Hematol. 1997;34:3-8.
18. Heintz APM, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. Int J Gynecol Obstet. 2003;83:135-166.
19. Ott I, Gust R. Non platinum metal complexes as anti-cancer drugs. Arch Pharm. 2007;340:117-126.
20. Thrall JH. Nanotechnology and medicine. Radiology. 2004;230: 315-318.
21. Dresco PA, Zaitsev VS, Gambino RJ, et al. Preparation and properties of magnetite and polymer magnetite nanoparticles. Langmuir. 1999;15:1945-1951.
22. Willner I, Willner B. Functional nanoparticle architectures for sensoric, optoelectronic and bioelectronic applications. Pure Appl Chem. 2002;74:1773-1783.
23. Thomas K, Sayre P. Research strategies for safety evaluation of nano-materials, Part I: Evaluating the human health implications of exposure to nanoscale materials. Toxicol Sci. 2005;87:316-321.
24. Chen D H, Liao MH. Preparation and characterization of YADH-bound magnetic nanoparticles. J Mol Catal B. 2002;16:283-291.
25. Hu Y, Jarillon S, Dubernet C, et al. On the mechnism of action of doxorubicin encapsulation in nanospheres for the reversal of mutidrugresistance. Cancer Chemother Pharmacol. 1996;37:556-560.
26. Soma CE, Dubernet C, Bentolila D, et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin Ain polyalkyleyanoacrylate nanoparticles. Biomaterials. 2000;21:1-7.
27. Wong HL, Bendayan R, Rauth AM, et al. A mechaninstic study of enhanced doxorubicin uptake and potention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticles system. J Pharmacol Exp Ther. 2006;317:1372-1381.
28. Wong HL, Rauth AM, Bendayan R, et al. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res. 2006;23:1574-1585.
29. Zhou CG, Shen P, Cheng YY, et al. Quantitative study of the drug efflux kinetics from sensitive and MDR human breast cancer cells. Biochim Biophys Acta. 2007;7:1011-1020.
30. Zhang HR, Chen J, Li HJ. Establishment of drug-resistant ovarian cancer cell strain to cisplatin and expression of resistance related genes. China Tropical Medicine. 2006;6:2132-2134.
31. Wei SJ, Li HY, Shi J, et al. Recombin-antmutant human-TNF in reversing drug-resistance in ovarian cancer cell lineSKOV3/DDP and the related mechanism. Chinese Journal of Cancer Biotherapy, 2008;15:150-154.
32. Ludwig JA, Szakács G, Martin SE, et al. Selective toxicity of NSE73306 inmdr1- positive cells a new strategy to circumvent multidrug resistance in cancer. Cancer Res. 2006;66:4808-4815.
33. Huang Z. Bcl-2 family proteins as targets for anticancer drug design. Oncogene. 2000;19:6627-6631.